RCUS Arcus Biosciences Inc: Multiplikator nilai perusahaan marang pendapatan

Logo perusahaan publik arcusbio.com (RCUS)

Arcus Biosciences, Inc. (RCUS) possesses high scientific authority in developing targeted immuno-oncology agents. A diversification strategy through partnerships with industry behemoths mitigates risks, as the company's price-to-sales trend on GURU.Markets illustrates through valuation dynamics. The value 17581.70 serves as the current metric level, while the asset's market price is based exclusively on the success of clinical trials.

Nilai perusahaan marang pendapatan: Arcus Biosciences Inc (RCUS) kanggo 23.11.2025 - 20.11.2026

arcusbio.com - rincian analitis lan metrik utama (RCUS)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:Arcus Biosciences, Inc. RCUS
Sampel barang Arcus Biosciences, Inc.

This ratio determines the market value of the business, including net debt, relative to sales volume. By analyzing the enterprise value-to-revenue level, an investor identifies the degree of asset overheating relative to actual cash flows. The metric eliminates the impact of leverage, exposing the true fundamental valuation. For Arcus Biosciences, Inc. (RCUS), this allows for an assessment of how much the market has priced in the success of immuno-oncology developments and the effectiveness of strategic partnerships. A sharp increase in the indicator may signal inflated expectations for future clinical successes.

Analisis pesaing Arcus Biosciences, Inc.

IBRX (immunitybio.com) - Rasio nilai perusahaan marang pendapatan|Immunocore Corp (IMCR) - Rasio nilai perusahaan marang pendapatan|Multiplikator nilai perusahaan marang pendapatan Janux Pharma (JANX)|Nilai perusahaan marang pendapatan ZYME|TNGX - Rasio nilai perusahaan marang dodolan|Nilai perusahaan marang pendapatan IOVA (Iovance)|Koefisien nilai perusahaan marang pendapatan IMTX|Multiplikator EV/Sales XNCR (Xencor)|Nilai bisnis marang pendapatan CMPX|replimune.com - Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Lyell Pharma|Innate Pharma S.A. (IPHA) - Rasio nilai perusahaan marang pendapatan|Pyxis Oncology Inc. - Nilai bisnis marang pendapatan|CGEN (Compugen Limited) - Multiplikator EV/Sales|Multiplikator EV/Sales IO Biotech Inc|Rasio nilai perusahaan marang pendapatan Sutro Biopharma (STRO)|INKT: Nilai perusahaan marang volume dodolan|Werewolf Therapeutics, Inc. - Nilai perusahaan marang pendapatan|Immix (IMMX) - Multiplikator nilai perusahaan marang pendapatan|ALX Oncology Holdings Inc. - Multiplikator EV/Sales|CUE - Multiplikator EV/Sales|PDSB: Multiplikator EV/Sales|Multiplikator nilai perusahaan marang pendapatan Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - Multiplikator EV/Sales|Nilai perusahaan marang pendapatan Liminatus Pharma (LIMN)|Multiplikator EV/Sales LVTX|Koefisien nilai perusahaan marang pendapatan NXTC|Leap Therapeutics, Inc. - Nilai perusahaan marang pendapatan|INTS: Rasio nilai perusahaan marang pendapatan|Sensei Biotherapeutics Inc - Multiplikator EV/Sales|TOVX: Rasio nilai perusahaan marang pendapatan|gritstonebio.com (GRTS) - Rasio nilai perusahaan marang pendapatan|Rasio nilai perusahaan marang pendapatan KA|Rasio nilai perusahaan marang pendapatan NexImmune, Inc.|Rasio nilai perusahaan marang pendapatan TSBX (Turnstone Biologics)|Nilai perusahaan marang pendapatan VCNX (Vaccinex, Inc.)|Koefisien nilai perusahaan marang pendapatan HARP